bamlanivimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
primate origin	5453	2423943-37-5

Description:

Molecule	Description
Molfile Synonyms: bamlanivimab LY-CoV555 LY3819253	Effective April 16, 2021, FDA revoked the EUA for use of bamlanivimab alone (monotherapy) for the treatment of mild to moderate COVID-19. The EUA for use of bamlanivimab in a combined regimen with etesevimab remains unchanged. Bamlanivimab is a recombinant neutralizing human IgG1kappa monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region. Bamlanivimab binds to spike protein and blocks spike protein attachment to the human ACE2 receptor with an IC50 value of 0.025 μg/mL. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

bamlanivimab
LY-CoV555
LY3819253

Effective April 16, 2021, FDA revoked the EUA for use of bamlanivimab alone (monotherapy) for the treatment of mild to moderate COVID-19. The EUA for use of bamlanivimab in a combined regimen with etesevimab remains unchanged. Bamlanivimab is a recombinant neutralizing human IgG1kappa monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region. Bamlanivimab binds to spike protein and blocks spike protein attachment to the human ACE2 receptor with an IC50 value of 0.025 μg/mL.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Nov. 11, 2020	FDA	Eli Lilly and Company

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	619.18	46.67	334	5115	245187	63238386
COVID-19 pneumonia	437.83	46.67	121	5328	14088	63469485
Oxygen saturation decreased	387.22	46.67	176	5273	88409	63395164
Dyspnoea	385.82	46.67	368	5081	660945	62822628
Hypoxia	264.60	46.67	120	5329	59672	63423901
Flushing	229.75	46.67	117	5332	74970	63408603
Chest discomfort	200.84	46.67	122	5327	109847	63373726
Chills	134.17	46.67	96	5353	113282	63370291
Pyrexia	119.25	46.67	172	5277	470306	63013267
Chest pain	94.58	46.67	104	5345	215855	63267718
Cough	82.74	46.67	113	5336	292630	63190943
Dizziness	67.63	46.67	127	5322	429798	63053775
Drug ineffective	56.16	46.67	11	5438	1044754	62438819
Nausea	50.62	46.67	174	5275	854297	62629276
Fibrin D dimer increased	49.59	46.67	18	5431	5016	63478557

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	621.47	43.42	253	5302	52804	34898572
Oxygen saturation decreased	513.65	43.42	222	5333	53596	34897780
COVID-19 pneumonia	494.17	43.42	159	5396	16808	34934568
Hypoxia	366.49	43.42	177	5378	54918	34896458
Dyspnoea	301.64	43.42	331	5224	376451	34574925
Chills	299.53	43.42	176	5379	80867	34870509
Pyrexia	183.65	43.42	243	5312	332770	34618606
Cough	106.81	43.42	125	5430	150015	34801361
Flushing	87.83	43.42	58	5497	32362	34919014
Tachycardia	81.83	43.42	83	5472	84689	34866687
Acute respiratory failure	80.56	43.42	54	5501	30874	34920502
Body temperature increased	77.98	43.42	43	5512	17325	34934051
Respiratory failure	66.61	43.42	84	5471	108488	34842888
Fibrin D dimer increased	66.05	43.42	25	5530	4219	34947157
Chest discomfort	61.15	43.42	58	5497	54472	34896904
Hyperhidrosis	56.95	43.42	65	5490	75627	34875749
Chest pain	56.46	43.42	84	5471	126678	34824698

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	1146.44	38.76	578	10386	229659	79503765
COVID-19 pneumonia	847.15	38.76	263	10701	28586	79704838
Oxygen saturation decreased	823.73	38.76	385	10579	128662	79604762
Dyspnoea	664.55	38.76	691	10273	856334	78877090
Hypoxia	596.55	38.76	288	10676	102955	79630469
Chills	421.40	38.76	266	10698	159968	79573456
Flushing	313.44	38.76	178	10786	88090	79645334
Pyrexia	276.91	38.76	398	10566	678311	79055113
Chest discomfort	229.39	38.76	173	10791	137871	79595553
Cough	180.22	38.76	236	10728	366553	79366871
Chest pain	137.43	38.76	181	10783	282123	79451301
Acute respiratory failure	113.08	38.76	81	10883	59460	79673964
Tachycardia	112.22	38.76	130	10834	177638	79555786
Fibrin D dimer increased	108.95	38.76	42	10922	8612	79724812
Body temperature increased	107.03	38.76	70	10894	44350	79689074
Respiratory failure	105.41	38.76	127	10837	180784	79552640
Hyperhidrosis	90.92	38.76	108	10856	151384	79582040
Tachypnoea	83.32	38.76	53	10911	32010	79701414
Drug ineffective	79.76	38.76	25	10939	1080888	78652536
Dizziness	70.33	38.76	194	10770	526247	79207177
Nausea	64.02	38.76	280	10684	956916	78776508
Lung opacity	57.68	38.76	23	10941	5151	79728273
Troponin increased	55.49	38.76	34	10930	19221	79714203
Off label use	50.98	38.76	31	10933	907184	78826240
Blood pressure decreased	50.12	38.76	65	10899	99401	79634023
Mental status changes	47.32	38.76	52	10912	66907	79666517
Feeling hot	46.81	38.76	49	10915	59685	79673739
Wrong product administered	45.45	38.76	23	10941	8989	79724435
Drug interaction	45.38	38.76	3	10961	415180	79318244
Lung infiltration	40.80	38.76	30	10934	22882	79710542
Tremor	40.70	38.76	79	10885	170004	79563420
Hypotension	39.05	38.76	141	10823	440176	79293248

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000998	Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
COVID-19	indication	840539006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Spike glycoprotein	Glycoprotein		SPIKE_SARS2		Kd	10.15		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D11936	KEGG_DRUG
45I6OFJ8QH	UNII
C5421805	UMLSCUI
CHEMBL4650379	ChEMBL_ID
DB15718	DRUGBANK_ID
11325	IUPHAR_LIGAND_ID
018553	NDDF
1119335003	SNOMEDCT_US
1119336002	SNOMEDCT_US
4039827	VANDF
2463114	RXNORM
340769	MMSL
39004	MMSL
d09678	MMSL
C000711749	MESH_SUPPLEMENTAL_RECORD_UI
11876	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bamlanivimab	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7910	INJECTION, SOLUTION	35 mg	INTRAVENOUS	Emergency Use Authorization	29 sections
Bamlanivimab	HUMAN PRESCRIPTION DRUG LABEL	1	0002-7910	INJECTION, SOLUTION	35 mg	INTRAVENOUS	Emergency Use Authorization	29 sections